Heartflow (NASDAQ:HTFL) Director Julie Cullivan Sells 9,122 Shares

Heartflow, Inc. (NASDAQ:HTFL) Director Julie Cullivan sold 9,122 shares of the firm’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $25.00, for a total value of $228,050.00. Following the sale, the director directly owned 27,291 shares of the company’s stock, valued at $682,275. This represents a 25.05% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Heartflow Stock Down 7.6%

Shares of HTFL traded down $1.88 during trading hours on Friday, hitting $22.98. The company had a trading volume of 839,171 shares, compared to its average volume of 1,611,570. The business has a fifty day moving average of $28.43 and a 200-day moving average of $30.96. The firm has a market cap of $1.96 billion and a price-to-earnings ratio of -12.70. Heartflow, Inc. has a 12 month low of $20.13 and a 12 month high of $41.22.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on HTFL. Wells Fargo & Company started coverage on Heartflow in a report on Wednesday, January 28th. They set an “overweight” rating and a $38.00 price objective for the company. Canaccord Genuity Group boosted their price target on Heartflow from $39.00 to $40.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. JPMorgan Chase & Co. upped their price objective on Heartflow from $36.00 to $40.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reissued a “sell (d)” rating on shares of Heartflow in a report on Monday, December 29th. Finally, Stifel Nicolaus boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Five analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Institutional Investors Weigh In On Heartflow

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wellington Management Group LLP bought a new position in Heartflow in the 3rd quarter valued at approximately $164,263,000. Baillie Gifford & Co. acquired a new position in shares of Heartflow during the third quarter worth $101,182,000. Schusterman Interests LLC bought a new position in shares of Heartflow in the 3rd quarter valued at $65,274,000. Capricorn Investment Group LLC bought a new stake in Heartflow during the 4th quarter worth $48,178,000. Finally, Vanguard Group Inc. bought a new position in Heartflow in the third quarter valued at about $48,871,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.